This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teshima, T. Articles by Ferrara, J. L. M. Search for Related Content PubMed PubMed Citation Articles by Teshima, T. Articles by Ferrara, J. L. M.

Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation¹

Departments of Internal Medicine and Pediatrics, University of Michigan Cancer Center, Ann Arbor, Michigan 48109-0942 [T. T., J. L. M. F.] and Departments of Adult Oncology [N. M., S. G., G. D.] and Pediatric Oncology [G. R. H., L. P.], Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

Allogeneic bone marrow transplantation (BMT) is currently restricted to hematological malignancies because of a lack of antitumor activity against solid cancers. We have tested a novel treatment strategy to stimulate specific antitumor activity against a solid tumor after BMT by vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). Using the B16 melanoma model, we found that vaccination elicited potent antitumor activity in recipients of syngeneic BMT in a time-dependent fashion, and that immune reconstitution was critical for the development of antitumor activity. Vaccination did not stimulate antitumor immunity after allogeneic BMT because of the post-BMT immunodeficiency associated with graft-versus-host disease (GVHD). Remarkably, vaccination was effective in stimulating potent and long-lasting antitumor activity in recipients of T-cell-depleted (TCD) allogeneic bone marrow. Recipients of TCD bone marrow who showed significant immune reconstitution by 6 weeks after BMT developed B16-specific T-cell-cytotoxic, proliferative, and cytokine responses as a function of vaccination. T cells derived from donor stem cells were, therefore, able to recognize tumor antigens, although they remained tolerant to host histocompatibility antigens. These results demonstrate that GM-CSF-based tumor cell vaccines after allogeneic TCD BMT can stimulate potent antitumor effects without the induction of GVHD, and this strategy has important implications for the treatment of patients with solid malignancies.

This article has been cited by other articles:

				S. Zarei, F. Schwenter, P. Luy, M. Aurrand-Lions, P. Morel, M. Kopf, G. Dranoff, and N. Mach Role of GM-CSF signaling in cell-based tumor immunization Blood, June 25, 2009; 113(26): 6658 - 6668. [Abstract] [Full Text] [PDF]

				C. M. Capitini, S. Herby, M. Milliron, M. R. Anver, C. L. Mackall, and T. J. Fry Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect Blood, May 14, 2009; 113(20): 5002 - 5009. [Abstract] [Full Text] [PDF]

				C. Fonseca, R. Soiffer, V. Ho, M. Vanneman, M. Jinushi, J. Ritz, D. Neuberg, R. Stone, D. DeAngelo, and G. Dranoff Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction Blood, February 19, 2009; 113(8): 1681 - 1688. [Abstract] [Full Text] [PDF]

				Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF]

				M.-A. Perales, A. Diab, A. D. Cohen, D. W. Huggins, J. A. Guevara-Patino, V. M. Hubbard, M. E. Engelhorn, A. A. Kochman, J. M. Eng, F. Mortazavi, et al. DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation J. Immunol., September 15, 2006; 177(6): 4159 - 4167. [Abstract] [Full Text] [PDF]

				M. Ohashi, A. Kobayashi, H. Hara, Y. Miura, K. Yoshida, M. Kushida, Y. Ikarashi, M. Mandai, M. Kitajima, T. Yoshida, et al. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2208 - 2215. [Abstract] [Full Text] [PDF]

				L. A. Emens and E. M. Jaffee Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy Cancer Res., September 15, 2005; 65(18): 8059 - 8064. [Abstract] [Full Text] [PDF]

				Y. Maeda, P. Reddy, K. P. Lowler, C. Liu, D. K. Bishop, and J. L. M. Ferrara Critical role of host {gamma}{delta} T cells in experimental acute graft-versus-host disease Blood, July 15, 2005; 106(2): 749 - 755. [Abstract] [Full Text] [PDF]

				L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]

				Y. Maeda, R. B. Levy, P. Reddy, C. Liu, S. G. Clouthier, T. Teshima, and J. L. M. Ferrara Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease Blood, March 1, 2005; 105(5): 2023 - 2027. [Abstract] [Full Text] [PDF]

				D. Hashimoto, S. Asakura, S. Miyake, T. Yamamura, L. Van Kaer, C. Liu, M. Tanimoto, and T. Teshima Stimulation of Host NKT Cells by Synthetic Glycolipid Regulates Acute Graft-versus-Host Disease by Inducing Th2 Polarization of Donor T Cells J. Immunol., January 1, 2005; 174(1): 551 - 556. [Abstract] [Full Text] [PDF]

				M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]

				M. Stelljes, R. Strothotte, H.-G. Pauels, C. Poremba, M. Milse, C. Specht, J. Albring, G. Bisping, C. Scheffold, T. Kammertoens, et al. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets Blood, August 15, 2004; 104(4): 1210 - 1216. [Abstract] [Full Text] [PDF]

				G. C. Hildebrandt, L. A. Corrion, K. M. Olkiewicz, B. Lu, K. Lowler, U. A. Duffner, B. B. Moore, W. A. Kuziel, C. Liu, and K. R. Cooke Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome J. Immunol., August 1, 2004; 173(3): 2050 - 2059. [Abstract] [Full Text] [PDF]

				U. A. Duffner, Y. Maeda, K. R. Cooke, P. Reddy, R. Ordemann, C. Liu, J. L. M. Ferrara, and T. Teshima Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease J. Immunol., June 15, 2004; 172(12): 7393 - 7398. [Abstract] [Full Text] [PDF]

				M. Zoller Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host J. Immunol., December 15, 2003; 171(12): 6941 - 6953. [Abstract] [Full Text] [PDF]

				M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF]

				T. Teshima, P. Reddy, C. Liu, D. Williams, K. R. Cooke, and J. L. M. Ferrara Impaired thymic negative selection causes autoimmune graft-versus-host disease Blood, July 15, 2003; 102(2): 429 - 435. [Abstract] [Full Text] [PDF]

				A. E. M. Dirkx, M. G. A. oude Egbrink, M. J. E. Kuijpers, S. T. van der Niet, V. V. T. Heijnen, J. C. A. B.-t. Steege, J. Wagstaff, and A. W. Griffioen Tumor Angiogenesis Modulates Leukocyte-Vessel Wall Interactions in Vivo by Reducing Endothelial Adhesion Molecule Expression Cancer Res., May 1, 2003; 63(9): 2322 - 2329. [Abstract] [Full Text] [PDF]

				L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras Blood, February 15, 2003; 101(4): 1645 - 1652. [Abstract] [Full Text] [PDF]

				S. Hummel, D. Wilms, M. Vitacolonna, and M. Zoller Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host J. Leukoc. Biol., November 1, 2002; 72(5): 898 - 912. [Abstract] [Full Text] [PDF]

				T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation Cancer Res., February 1, 2002; 62(3): 796 - 800. [Abstract] [Full Text] [PDF]

				W. Asavaroengchai, Y. Kotera, and J. J. Mule Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery PNAS, January 22, 2002; 99(2): 931 - 936. [Abstract] [Full Text] [PDF]